RLS enters strategic agreement with Eckert & Ziegler
RLS Radiopharmacies has entered a strategic agreement with Eckert & Ziegler, which will see all 31 of RLS’s radiopharmacies equipped with Eckert & Ziegler’s GalliaPharm generators.
The RLS radiopharmacy network will use these generators to produce gallium-68-based (Ga-68) radiopharmaceuticals for PET imaging and treatment planning for patients with neuroendocrine tumors and prostate cancer.
To date, RLS has installed Eckert & Ziegler’s GalliaPharm generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June 2024.
RLS added that it is also building ...
Source: AuntMinnie.com Headlines - April 4, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
The rise of theranostics: Part 2 -- Moving into communities
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. That has changed and the field of theranostics is expanding rapidly in various ways, as described in part 1 of AuntMinnie.com's series on the rise of theranostics.
However, few freestanding theranostics centers exist today. Even if some private urology, radiation oncology practices, or radiologist groups are building the ability to perform theranostics, experts are cautious about patient management, radiation safety, and the risk of unnecessary imaging. They're also mindful of the multiple dedicated teams required to build a thera...
Source: AuntMinnie.com Headlines - April 4, 2024 Category: Radiology Authors: Liz Carey Tags: Practice Management Radiation Oncology/Therapy Nuclear Medicine Medicolegal Genitourinary Radiology Source Type: news
Hoag launches Pylarify PET prostate cancer trial
Hoag healthcare system in Orange County, CA, has launched a clinical trial to assess the prostate cancer PET imaging radiotracer Pylarify in patients newly diagnosed with intermediate disease.
Currently, the radiotracer is approved in the U.S. for diagnosed prostate cancer patients to identify suspected metastasis or recurrence of the disease. The trial will use Pylarify with whole-body PET/CT scans in men with favorable intermediate prostate cancer, including Gleason Score 3+4 tumors, Hoag said.
The phase IV open-label multicenter trial will ultimately assess the safety and accuracy of the approach in an estimated 274 p...
Source: AuntMinnie.com Headlines - April 3, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
MRI + Blood Test Results May Cut Unnecessary Biopsies for Prostate Cancer
TUESDAY, April 2, 2024 -- Prostate biopsies may not be necessary for patients with equivocal or negative magnetic resonance imaging (MRI) results and low prostate-specific antigen density (PSAD), according to a study published online March 29... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2024 Category: Pharmaceuticals Source Type: news
New Trials in Prostate Cancer: Could Your Patient Benefit? New Trials in Prostate Cancer: Could Your Patient Benefit?
Perhaps one of your patients could benefit from a clinical trial that has recently opened in prostate cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 2, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Some Cancer Patients Can Find It Hard to Tell Family and Friends
(MedPage Today) -- Ever since Anthony Bridges found out he had prostate cancer 6 years ago, he hasn't stopped talking about it. He told his Facebook friends immediately.
Now, the 68-year-old man from Georgia spends time working with others to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - March 31, 2024 Category: Hematology Source Type: news
Cancer signs could be spotted years before symptoms, says new research institute
Tests that can identify early changes in cells would give doctors more time to offer treatment, say Cambridge researchersScientists at a recently opened cancer institute at Cambridge University have begun work that is pinpointing changes in cells many years before they develop into tumours. The research should help design radically new ways to treat cancer, they say.TheEarly Cancer Institute– which has just received £11m from an anonymous donor – is focused on finding ways to tackle tumours before they produce symptoms. The research will exploit recent discoveries which have shown that many people develop precancerous...
Source: Guardian Unlimited Science - March 31, 2024 Category: Science Authors: Robin McKie Science Editor Tags: Cancer research Medical research Health Science Society Health policy Prostate cancer University of Cambridge UK news Source Type: news
Colman Domingo, LeVar Burton, Viola Davis and More Pay Tribute to Louis Gossett Jr.: “You Will Continue to Inspire”
On Friday, Gossett’s family announced that the Officer and a Gentlemen star passed away at the age of 87. The cause of death is unknown, but Gossett announced in 2010 that he had prostate cancer. In a statement obtained by The Hollywood Reporter, his family said, “It is with our heartfelt regret…#hollywoodreporter #gentleman #gunnerysgt #emilfoley #anacademyaward #sidneypoitier #hollywood #colorpurple #fantasiabarrino #louisgossettjr (Source: Reuters: Health)
Source: Reuters: Health - March 29, 2024 Category: Consumer Health News Source Type: news
Relugolix Beneficial for Prostate Cancer Patients Undergoing Radiotherapy
FRIDAY, March 29, 2024 -- For patients with localized and advanced prostate cancer receiving radiotherapy, relugolix achieves sustained castration, according to a study published online March 7 in JAMA Oncology.Daniel E. Spratt, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 29, 2024 Category: Pharmaceuticals Source Type: news
Some cancer patients can find it hard to tell family and friends about their diagnosis: ‘You’re dealing with this all alone’
Ever since Anthony Bridges found out he had prostate cancer six years ago, he hasn’t stopped talking about it. He told his Facebook friends immediately. Now, the 68-year-old man from Georgia spends time working with others to encourage other men to talk to their doctor about getting screened. Not…#anthonybridges #georgia #defense #lloydaustin #wales #princewilliam #otisbrawley #bigc #bobdole #bettyford (Source: Reuters: Health)
Source: Reuters: Health - March 28, 2024 Category: Consumer Health News Source Type: news
Accuray touts data presented at Radiosurgery Society Meeting
Accuray is touting data presented at the 2024 Radiosurgery Society (RSS) meeting in Chicago, which the company said supports the use of the CyberKnife System in treating high-risk and recurrent prostate cancer.
CyberKnife allows for treatment of prostate cancer using stereotactic body radiation therapy (SBRT), where high doses of radiation are delivered over a shorter duration than traditional treatments. The company said that CyberKnife offers a treatment option for prostate tumors in four to five sessions.
Data presented at the meeting suggested that at three years follow-up, the system achieved favorable biochemical c...
Source: AuntMinnie.com Headlines - March 26, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
April 2024
Comparing Side Effects of Prostate Cancer Treatments
Trouble With Touch? : Feeling Your World
Appendix Pain : Preventing Appendicitis Complications
All About Acne
Migraine Trainer App (Source: NIH News in Health)
Source: NIH News in Health - March 26, 2024 Category: Consumer Health News Source Type: news
The rise of theranostics: Part 1 -- Gaining momentum
Since the U.S. Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research.Theranostics pairs diagnostic biomarkers that can be visualized on nuclear medicine imaging with therapeutic agents that share a specific target in diseased cells or tissues. After the therapeutic agent binds to the cancer cells, the tumors are treated in such a way that aims to prevent collateral damage to healthy cells and improve overall outcomes.Theranostics isn’t new; nuclear medicine d...
Source: AuntMinnie.com Headlines - March 26, 2024 Category: Radiology Authors: Liz Carey Tags: Practice Management Molecular Imaging Radiation Oncology/Therapy Nuclear Medicine Source Type: news
MRI-Guided TULSA Effective at Five Years for Localized Prostate Cancer
MONDAY, March 25, 2024 -- For the treatment of localized prostate cancer, in-bore, magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) results in favorable outcomes at five years, including durable oncologic control and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2024 Category: Pharmaceuticals Source Type: news
Helping Poorer Patients Pay for Prostate Cancer Meds Keeps Them on Treatment
MONDAY, March 25, 2024— Men with prostate cancer treated at hospitals participating in a special drug-pricing program were more likely to stick to their therapy than patients elsewhere, new research reveals.
The federal 340B Drug Program... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 25, 2024 Category: General Medicine Source Type: news
